Akorn intros generic Lotemax
Akorn is debuting loteprednol etabonate ophthalmic suspension, 0.5%.
The product is the generic of Bausch + Lomb’s Lotemax and first to market generic for this product, the company said.
“This launch underscores our ability to execute on development and manufacturing of complex ophthalmic suspensions. With the launch of this first-to-market generic, we are pleased to offer patients additional treatment options for ocular inflammation,” Akorn’s president and CEO, Douglas Boothe said.
The product is indicated for the treatment of post-operative inflammation following ocular surgery and the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.
Loteprednol etabonate ophthalmic suspension, 0.5% had a market value of approximately $90 million for the 12 months ended April 2019, according to IQVIA.
The product is the generic of Bausch + Lomb’s Lotemax and first to market generic for this product, the company said.
“This launch underscores our ability to execute on development and manufacturing of complex ophthalmic suspensions. With the launch of this first-to-market generic, we are pleased to offer patients additional treatment options for ocular inflammation,” Akorn’s president and CEO, Douglas Boothe said.
The product is indicated for the treatment of post-operative inflammation following ocular surgery and the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.
Loteprednol etabonate ophthalmic suspension, 0.5% had a market value of approximately $90 million for the 12 months ended April 2019, according to IQVIA.